On the other hand, a considerable increase in Ang-2 concentration was detected in 16 NSCLC at the third cycle of treatment who received platinum-based chemotherapy in combination with the anti-VEGF treatment (p = 0.044, Figure 5A). This evidence concerns the gene ANGPT2 and non-small cell lung carcinoma.